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Abstract 
Albuminuria and reduced glomerular filtration rate are manifestations of chronic kidney 
disease (CKD) that predict end-stage renal disease, acute kidney injury, cardiovascular 
disease and death. We hypothesized that SNPs identified in association with the 
estimated glomerular filtration rate (eGFR) would also be associated with albuminuria. 
Within the CKDGen Consortium cohort (n= 31 580, European ancestry), we tested 16 
eGFR-associated SNPs for association with the urinary albumin-to-creatinine ratio 
(UACR) and albuminuria [UACR >25 mg/g (women); 17 mg/g (men)]. In parallel, within 
the CARe Renal Consortium (n= 5569, African ancestry), we tested seven eGFR-
associated SNPs for association with the UACR. We used a Bonferroni-corrected P-value 
of 0.003 (0.05/16) in CKDGen and 0.007 (0.05/7) in CARe. We also assessed whether 
the 16 eGFR SNPs were associated with the UACR in aggregate using a beta-weighted 
genotype score. In the CKDGen Consortium, the minor A allele of rs17319721 in the 
SHROOM3 gene, known to be associated with a lower eGFR, was associated with lower 
ln(UACR) levels (beta = −0.034, P-value = 0.0002). No additional eGFR-associated SNPs 
met the Bonferroni-corrected P-value threshold of 0.003 for either UACR or 
albuminuria. In the CARe Renal Consortium, there were no associations between SNPs 
and UACR with a P< 0.007. Although we found the genotype score to be associated with 
albuminuria (P= 0.0006), this result was driven almost entirely by the known SHROOM3 
variant, rs17319721. Removal of rs17319721 resulted in a P-value 0.03, indicating a 
weak residual aggregate signal. No alleles, previously demonstrated to be associated 
with a lower eGFR, were associated with the UACR or albuminuria, suggesting that there 
may be distinct genetic components for these traits.  
 
INTRODUCTION 
Chronic kidney disease (CKD) affects ∼26 million adults in the USA (1). It is an illness of 
major public health importance as affected individuals experience a substantially 
increased risk of end-stage renal disease and need for dialysis, as well as a dramatic 
excess in cardiovascular morbidity and mortality (2). CKD is defined as persistent kidney 
damage marked either by the presence of albuminuria or a reduced estimated 
glomerular filtration rate (eGFR) (3). For any given level of eGFR, albuminuria is 
associated with increased CVD and all-cause mortality outcomes (4). Furthermore, the 
prevalence of albuminuria increases dramatically as the GFR falls, from <10% in those 
with a preserved GFR to almost 60% in those with advanced CKD (1). Furthermore, 
albuminuria is the strongest known risk factor for the progression of CKD, such that the 
risk of end-stage kidney disease is 10 times higher in people with a preserved GFR and 
albuminuria compared with those with the same GFR but no albuminuria (5).  
We have previously shown that a reduced eGFR and albuminuria are associated with 
differential risk factor profiles (6). Further, only one-quarter of individuals with CKD 
have albuminuria (6). This is corroborated by data from the National Health and 
Nutrition Examination Surveys (NHANES), which showed that increased trends in the 
prevalence of albuminuria, but not CKD defined as an eGFR <60 ml/min/1.73 m2, can 
be explained by hypertension and diabetes (1). Taken together, these data suggest 
potential differential etiologies for albuminuria and a reduced GFR.  
Genome-wide association studies (GWAS) have identified 16 loci for the eGFR in 
European populations from the CKDGen Consortium (7,8). We have additionally 
identified seven SNPs for the eGFR in African-American populations from the CARe 
Renal Consortium (9,10). Notably, only one locus at SHROOM3 has been identified 
previously as being associated with both the urinary albumin-to-creatinine ratio (UACR) 
and the eGFR, leading us to speculate that the genetic architecture of the eGFR and the 
UACR as identified through GWAS in population-based cohorts may be different (9). 
Indeed, other studies have shown that there is a weak genetic concordance between 
both traits (11). To investigate this more comprehensively, we performed a targeted SNP 
analysis using 16 eGFR-associated SNPs previously identified in Europeans (7) and 7 
eGFR-associated SNPs previously identified in African-Americans (10) to determine 
whether these SNPs were also associated with the UACR. Given the known inverse 
associations between the eGFR and the UACR, we hypothesized that alleles associated 
with a lower eGFR would also be associated with an increased UACR. We tested this in 
the existing CKDGen albuminuria and CARe Renal Consortium data sets (9,10).  
 
RESULTS 
All study participants were of European (CKDGen Consortium) or African-American 
(CARe Renal Consortium) descent (9,10). Study sample characteristics can be found in 
Supplementary Material, Table S1 and S2.  
UACR results 
Association results for the 16 eGFR-associated SNPs with the UACR in the CKDGen 
Consortium can be found in Table 1. As previously reported, there was a significant 
association with rs17319721 in SHROOM3 on chromosome 4. The UACR levels were 
lower per copy of the A allele at rs17319721 (P-value = 0.0002), whereas the eGFR 
levels were also lower in our previously published analysis. No additional SNPs met the 
Bonferroni P-value threshold of 0.003 (0.05/16).  
 
Albuminuria results 
Association results for albuminuria from the CKDGen Consortium can be found in Table 
2. Similar to what we observed for the UACR, only one SNP reached significance. The A 
allele at rs17319721 in SHROOM3 was associated with a lower odds ratio for 
albuminuria (P-value = 1.87E-06; OR = 0.88). No additional SNPs met the Bonferroni P-
value threshold of 0.003.  
 
African-American ancestry UACR results 
Association results for the UACR in the CARe Renal Consortium can be found in Table 3. 
Of the seven variants tested, none was associated at P< 0.007.  
 
Concordance between UACR and eGFR 
In general, higher eGFR levels are associated with lower UACR levels (for example, 
Framingham Heart Study correlation = −0.14; P-value <0.001), leading us to 
hypothesize that alleles associated with a lower eGFR would be associated with a higher 
UACR, most notably for rs17319721 at the SHROOM3 locus. However, in the CKDGen 
Consortium, of the 16 variants tested, only 5 were in this expected direction, whereas 
11 were in the opposite direction (Fig. 1). We observed similar patterns of discordance in 
our African-American participants from the CARe Renal Consortium. Of the seven 
variants tested, only two showed associations in the hypothesized direction.  
 
View larger version: 
Figure 1. 
Scatter plot of SNP effects on the eGFR and the UACR. Quadrants labeled (A) (lower eGFR 
effect size, higher UACR effect size) and (D) (higher eGFR effect size, lower UACR effect 
size) represent associations consistent with the observed correlation of the eGFR and 
the UACR; quadrants labeled (B) (higher eGFR effect size, higher UACR effect size) and 
(C) (lower eGFR effect size, lower UACR effect size) represent associations inconsistent 
with the observed correlation of the traits.  
Genotype score analysis 
In the CKDGen Consortium, we found that the 16-SNP genotype score weighted by the 
beta-coefficient was associated with albuminuria (P= 0.0006). However, this result was 
driven almost entirely by the SHROOM3 variant, rs17319721, known a priori to be 
associated with albuminuria. The removal of rs17319721 resulted in a P-value of 0.03, 
indicating a weak residual aggregate signal.  
 
DISCUSSION 
We observed no robust associations beyond SHROOM3, which we have previously 
reported, between eGFR-associated SNPs and the UACR. A similar lack of association 
was observed between eGFR-associated SNPs and the UACR in the CARe Renal 
Consortium. Although the genotype score analysis suggested a weak aggregate 
association signal, taken together, these results suggest differential genetic 
underpinnings, as identified from population-based GWAS, for these traits.  
Prior research supports our primary findings, which suggest a differential etiology 
between the eGFR and the UACR. First, both traits show unique associations with some 
clinical risk factors. For example, in a cross-classification analysis of the eGFR and 
albuminuria, we found that only a quarter of the participants had both a reduced eGFR 
and albuminuria (6). Participants with albuminuria in the absence of a reduced eGFR had 
a higher prevalence of smoking, diabetes and elevated triglycerides, whereas 
participants without albuminuria in the presence of a reduced eGFR had a lower 
prevalence of smoking and diabetes despite being older (6). Similar findings of 
differential risk factor associations with the eGFR when compared with the UACR have 
been observed in other studies including the Zuni Kidney Project (11). These data 
suggest that these traits may have disparate underlying biological mechanisms.  
Furthermore, weak genetic correlations between the eGFR and the UACR also support a 
differential underpinning for both traits. Prior work has documented a low genetic 
correlation (r = −0.002) between the eGFR and the UACR (12). Differential genetic 
correlations between each trait and the clinical risk factors have previously been shown; 
for example, the Zuni Kidney Project observed significant genetic correlations of the 
UACR with blood pressure, whereas none was observed with regard to the eGFR (11). 
Other studies have also documented unique genetic correlations for the UACR and the 
eGFR with other clinical risk factors, such as diabetes, hypertension, HDL and LDL 
(13,14). These results additionally corroborate our findings that there may be a distinct 
genetic architecture between the UACR and the eGFR.  
As albuminuria and a reduced GFR commonly coexist in advanced kidney disease, our 
finding of minimal overlap in the genetic underpinnings to these traits may appear 
counterintuitive from a clinical standpoint. However, it must be remembered that it is 
atypical for these traits to occur simultaneously in early kidney disease, such as is seen 
in the general population. For example, in NHANES, only 8% with a GFR >60 
ml/min/1.73 m2 have albuminuria, whereas the rate rises to 58% for those with a GFR 
15–29 ml/min/1.73 m2 (15). Furthermore, in kidney diseases characterized by 
albuminuria, such as diabetic nephropathy or focal segmental glomerulosclerosis, a 
normal or increased GFR is characteristic in early disease and a reduced GFR often only 
manifests as a late phenomenon (16). In comparison, diseases primarily characterized 
by a low GFR due to reduced functioning nephron mass, such as polycystic kidney 
disease, often do not manifest albuminuria until the disease is quite advanced (17). This 
time-varying relationship in the onset of these two traits is often due to a maladaptive 
response of one to the other, and distinct genetic influences would thus be expected to 
underlie them at these differing time-points. Our observations are consistent with these 
data, and support the existence of a complex, distinct and time-varying interplay of 
small to moderate genetic influences underlying these phenotypes in the general 
population. Importantly, the new understanding gained from such insights may 
ultimately lead to different approaches to disease prevention and treatment.  
It is therefore surprising that rs17319721 in SHROOM3 is associated with both a lower 
UACR and lower eGFR in the general population. Thus, reasons for the joint associations 
between this variant may be due to pleiotropic associations of this gene on both traits. 
SNPs in SHROOM3 have previously been shown to be associated with serum magnesium 
concentrations (18), and these SNPs are in linkage disequilibrium with our lead SNP (r2= 
0.85). Downstream effector proteins of SHROOM3 such as GTPase, Rho Kinases, Rap1 
and myosin II may also act interdependently to contribute to the gene's functionality 
(19). To the best of our knowledge, SNPs in SHROOM3 have primarily been associated 
with renal traits, suggesting a possible renal pleiotropic specificity to its actions. Further 
functional work should focus on a better understanding of the mechanisms involved in 
the functional underpinnings of SHROOM3 in association with the UACR and the eGFR. 
Apart from pleiotropic actions, mechanisms may exist that are jointly associated with 
both a higher eGFR and higher UACR. For example, a higher GFR is associated with 
albuminuria in a variety of hyperfiltration states, including diabetes (20,21), sickle cell 
disease (22), hyperuricemia (23), hypertension (24) and primary aldosteronism (23).  
The strengths of this study include large albuminuria data sets from the CKDGen 
Consortium and the CARe Renal Consortium. The large sample sizes and the targeted 
gene approach increased the power to detect associations with the UACR and 
albuminuria, and the complementary samples allowed evaluation within both European 
and African ancestry populations. We also used a panel of well-established SNPs for the 
eGFR. Some limitations warrant mention. First, our African ancestry data set for the 
UACR was underpowered. Nonetheless, it is the largest data set of its kind in 
participants of African ancestry and makes an important point about the multi-ethnic 
nature of our results. Secondly, whereas our study indicates that there is little overlap in 
the common genetic determinants of the eGFR and the UACR in the general population, 
similar analyses in cohorts enriched for more advanced kidney disease or containing 
more cases of combined CKD and albuminuria may yet identify novel genes. Finally, as 
both the eGFR and the UACR may vary over time, testing for their association with 
longitudinal traits may yield different results. However, we were underpowered to test 
this hypothesis.  
Apart from the SHROOM3 locus, we observed no robust associations between the eGFR-
associated SNPs and the UACR in both Europeans and African-Americans, suggesting 
that there may be distinct genetic components to these traits as identified by 
population-based GWAS.  
 
MATERIALS AND METHODS 
Overall design study 
Genetic association testing for the UACR and albuminuria was performed in the CKDGen 
cohorts of European ancestry using existing GWAS meta-analysis data sets for the UACR 
and albuminuria (9). Additional association testing for the UACR was performed in the 
CARe cohorts of African-American ancestry (10).  
Study exposure 
Sixteen variants previously identified in a two-stage GWAS in association with the eGFR 
were specifically queried for association with the UACR and albuminuria in the CKDGen 
Consortium (n= 31 580) (7). Seven eGFR SNPs previously validated in a GWAS using 
participants of African ancestry were queried for association with the UACR in the CARe 
Renal Consortium (n= 5569) (10). Imputation scores for the 16 and 7 SNPs, respectively, 
are shown in Supplementary Material, Table S3.  
Outcomes 
For the CKDGen Consortium and CARe studies, the quantitative trait UACR was 
calculated in each participating study. The UACR was log-transformed for analysis; sex-
specific residuals that were age-adjusted were calculated as previously described (9). 
For the CKDGen studies, the dichotomous trait albuminuria was defined by a UACR >17 
mg/g for men and >25 mg/g for women (25,26). For the CARe studies, albuminuria was 
not secondarily analyzed due to the relatively small sample size.  
Statistical methods 
We used previously published meta-analysis data to look- up the results of the 16 eGFR 
SNPs in European Americans and the 7 eGFR SNPs in African -Americans for association 
with the UACR. To correct for multiple testing, we used a Bonferroni corrected P-value 
of 0.05/16 (0.003) in the CKDGen Consortium and 0.05/7 (0.007) in the CARe 
Consortium. In the CKDGen Consortium, we had 66% power to detect a beta-coefficient 
of 0.034 in a sample of 31 580 for an alpha of 0.003 (0.05/16). The power was lower in 
CARe due to the smaller sample size. To improve the power, we assessed whether the 
16 GFR SNPs in aggregate were associated with the UACR using a beta-weighted 
genotype score, as has been used in comparable analyses of blood pressure and lung 
function variants (27,28).  
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